Nectin Therapeutics Ltd. recently announced progress in its Phase 1 clinical trial of NTX1088, a novel targeted immunotherapy designed to overcome resistance to existing immune oncology treatments.

Avstera Therapeutics Corp has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for AVS100, a novel oral HDAC6

Replay, a genome writing company specializing in reprogramming biology through the design and delivery of large DNA, has partnered with Miltenyi Biotec

QPS Holdings, a global contract research organization (CRO) that provides drug discovery, preclinical research, bioanalysis, clinical trials, and clinical research services,

Mission Therapeutics has achieved a significant milestone as the US Food and Drug Administration has granted approval for its Investigational New Drug application for MTX652

Nerviano Medical Sciences S.r.l., a clinical-stage biotechnology company within the NMS group, recently announced a licensing agreement with Italfarmaco S.p.A.

Amgen has reported that the U.S. Food and Drug Administration has accepted its Biologics License Application for tarlatamab and granted Priority Review. Tarlatamab

Inductive Bio, a tech company specializing in machine learning, has come out of stealth mode with $4.3 million in funding. The seed round was led by Andreessen Horowitz

Eisai Co., Ltd. and Biogen Inc. have jointly announced the upcoming launch of the humanized anti-soluble aggregated amyloid-beta monoclonal antibody, "LEQEMBI Intravenous Infusion"

GigaGen Inc., a biotechnology company specializing in the development of innovative antibody drugs for immune deficiencies, infectious diseases, and checkpoint-resistant cancers, has received approval